Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

biotech_invest 136 posts  |  Last Activity: Aug 27, 2015 4:02 PM Member since: Mar 5, 1998
  • Reply to

    why can't TS deliver long acting insulin?

    by musherga Jun 15, 2015 10:59 AM
    biotech_invest biotech_invest Jun 15, 2015 12:31 PM Flag

    Well, insulin detemir is administrated once daily SC with evening meal or at bedtime.
    Initial dose
    Type 1 diabetes: Approximately one third of the total daily insulin requirements SC; rapid-acting or short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements; usual daily maintenance range is 0.5-1 unit/kg/day in divided doses; nonobese may require 0.4-0.6 unit/kg/day; obese may require 0.6-1.2 units/kg/day
    Type 2 diabetes inadequately controlled on oral medication: 10 units/day SC (or 0.1-0.2 unit/kg/day) in evening or divided q12hr
    Type 2 diabetes inadequately controlled on GLP-1 receptor agonist: 10 units/day SC given once daily in evening
    Since bioavailability of inhalable insulin is similar to SC, daily evening meal dosage 10-12 IU of detemir combined with diketopiperasine (co-dried microparticles) looks feasible. I don't see any technical obstacles to mix 4-8 IU of conventional insulin with 10-12 IU of detemir and co-dry them with DKP and load in one cartridge. MNKD or Sanofi can do it easy when detemir patent is expired (June 20, 2017).

    Sentiment: Strong Buy

  • Reply to

    why can't TS deliver long acting insulin?

    by musherga Jun 15, 2015 10:59 AM
    biotech_invest biotech_invest Jun 15, 2015 11:53 AM Flag

    come on, it's not correct question. TS technology can deliver even antibodies (high MW proteins) but the mechanisms of action of long acting (or basal) insulins are different: in one case it can be very slow sustained release from SC injection site because the insulin designed precipitate at this site (It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours); in other case the basal insulin is modified: t is an insulin analogue in which a fatty acid (myristic acid) is bound to the lysine amino acid at position B29. It is quickly absorbed after which it binds to albumin in the blood through its fatty acid at position B29. It then slowly dissociates from this complex.
    If you combine first one with TS it will act as fast-acting insulin (no SR) but second one (Insulin detemir) is very good candidate for TS-mediated lung delivery. Moreover, ideally MNKD can combine fast-acting meal time insulin with basal one (like detemir) and recommend use it with first meal of day. In this case diabetics will avoid any injections.

    Sentiment: Strong Buy

  • Reply to

    Truly Amazed

    by jtsendence Jun 15, 2015 10:24 AM
    biotech_invest biotech_invest Jun 15, 2015 11:19 AM Flag

    don't forget that pending news also can send stock much lower :-)
    My prediction is that Prana management plan to go with animal toxicity studies for PBT2. These studies are not very expensive but they will take at least 2 years. During these 2 years of waiting PRAN pps will be around cash level: if they have $40M cash now and 53M total outstanding shares be ready for pps $0.75-0.8 (for PRAN buyers at $1.40 it will be -50% losses and dead money for next couple years).
    I hope I'm not right and phase III HD will finally start in 2015: run up should be nice and pps may jump to $3-4.

  • biotech_invest biotech_invest Jun 15, 2015 11:08 AM Flag

    WOW! Best news for last 3 months!
    Insulin lispro (marketed by Eli Lilly and Company as "Humalog") is a fast acting insulin analog. Engineered through recombinant DNA technology, the penultimate lysine and proline residues on the C-terminal end of the B-chain are reversed. This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be immediately available for postprandial injections.
    Sanofi wants to see what postprandial insulin is more effective to keep normal blood glucose level: Afrezza PD vs. insulin lispro PD. If Afrezza win this competition Sanofi will buy MNKD immediately.

    Primary Outcome Measures:
    Assessment of PD parameter: Area under the glucose infusion rate curve within 24 hours after administration of the investigational medicinal product or until administration of rescue insulin (GIR-AUC0-end) [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

    Sentiment: Strong Buy

  • Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment

    Objective To examine the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, and cerebrospinal fluid biomarkers in adults with amnestic mild cognitive impairment or Alzheimer disease (AD).

    Design Randomized, double-blind, placebo-controlled trial.

    Setting Clinical research unit of a Veterans Affairs medical center.

    Participants The intent-to-treat sample consisted of 104 adults with amnestic mild cognitive impairment (n = 64) or mild to moderate AD (n = 40).

    Intervention Participants received placebo (n = 30), 20 IU of insulin (n = 36), or 40 IU of insulin (n = 38) for 4 months, administered with a nasal drug delivery device (Kurve Technology, Bothell, Washington).

    Main Outcome Measures Primary measures consisted of delayed story recall score and the Dementia Severity Rating Scale score, and secondary measures included the Alzheimer Disease's Assessment Scale–cognitive subscale (ADAS-cog) score and the Alzheimer's Disease Cooperative Study–activities of daily living (ADCS-ADL) scale.

    Results:
    Outcome measures were analyzed using repeated-measures analysis of covariance. Treatment with 20 IU of insulin improved delayed memory (P

    Sentiment: Strong Buy

  • So 400 will become 4000 during a few weeks and then 4000 will become 40000.
    Once diabetes patients try Afrezza they will re-fill it and advice other diabetics to try it. It will be real AVALANCHE that will bury MNKD shorts.

    Sentiment: Strong Buy

  • biotech_invest biotech_invest Jun 12, 2015 3:39 PM Flag

    they were not so lucky as BLUE employees :-)
    BLUE is also fake biotech but before investor will know truth the employees already sold stocks and got piles of money. Sure they have yachts now and LOL about BLUE investors.

    Jun 10, 2015 WALSH JEFFREY T.
    Officer
    11,000 Direct Automatic Sale at $178.61 - $181.33 per share. 1,980,0002
    Jun 9, 2015 COLE JASON
    Officer
    2,000 Direct Option Exercise at $22.53 per share. 45,060
    Jun 9, 2015 COLE JASON
    Officer
    2,000 Direct Automatic Sale at $184.62 - $188.24 per share. 373,0002
    Jun 2, 2015 SULLIVAN ERIC
    Officer
    416 Direct Automatic Sale at $190.20 per share. 79,123
    Jun 2, 2015 SULLIVAN ERIC
    Officer
    416 Direct Option Exercise at $20.70 - $24.47 per share. 9,3952
    Jun 1, 2015 FINER MITCHELL H.
    Officer
    15,000 Direct Option Exercise at $24.47 per share. 367,050
    Jun 1, 2015 FINER MITCHELL H.
    Officer
    15,000 Direct Automatic Sale at $188.59 - $195.07 per share. 2,877,0002
    May 22, 2015 FINER MITCHELL H.
    Officer
    15,000 Direct Automatic Sale at $166.39 - $173.39 per share. 2,548,0002
    May 22, 2015 FINER MITCHELL H.
    Officer
    15,000 Direct Option Exercise at $5.50 per share. 82,500
    May 15, 2015 FINER MITCHELL H.
    Officer
    15,000 Direct Option Exercise at $5.50 per share. 82,500
    May 15, 2015 DAVIDSON DAVID
    Officer
    2,000 Direct Automatic Sale at $153.04 - $159.26 per share. 312,0002
    May 15, 2015 DAVIDSON DAVID
    Officer
    2,000 Direct Option Exercise at $2.09 per share. 4,180
    May 15, 2015 FINER MITCHELL H.
    Officer
    15,000 Direct Automatic Sale at $153.04 - $159.26 per share. 2,342,0002
    May 11, 2015 WALSH JEFFREY T.
    Officer
    11,000 Direct Automatic Sale at $160.80 - $167.26 per share. 1,804,0002

  • biotech_invest biotech_invest Jun 12, 2015 11:52 AM Flag

    well, you got my thumb-up for this conclusion :-)
    My credo for investment strategy is: When millions say YES I answer NO
    Right now all investors are crazy about new player in AD field AXON but I have already shorted this #$%$.

  • biotech_invest biotech_invest Jun 12, 2015 11:05 AM Flag

    so, do you state that all funds analysts are just so stupid and don't see Prana huge potential? But you are so smart that predict 100% probability of success of drugs for AD, HD and PD?
    Looks like that you are Prana employee if you know about future success :-)

  • It is lowest IO number in my SCAM BIOTECH list (even ORMP Institutional Ownership is 11.55%).

    New Positions 2 700
    Sold Out Positions 6 222,881
    Why the majority of big holders are selling PRAN that has cures for AD, HD, PD and other terrible diseases?
    Do they know something?

    Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
    GARRISON BRADFORD & ASSOCIATES INC 03/31/2015 109,342 (500) (0.46) 162
    BANK OF AMERICA CORP /DE/ 03/31/2015 69,000 (3,000) (4.17) 102
    SUSQUEHANNA INTERNATIONAL GROUP, LLP 03/31/2015 49,121 (46,370) (48.56) 73
    COLUMBIA ASSET MANAGEMENT 03/31/2015 34,200 (5,250) (13.31) 51
    GROUP ONE TRADING, L.P. 03/31/2015 32,043 13,981 77.41 47
    MORGAN STANLEY 03/31/2015 24,650 (3,875) (13.59) 36
    KCG HOLDINGS, INC. 03/31/2015 17,205 (142,143) (89.2) 25
    NINE CHAPTERS CAPITAL MANAGEMENT LLC 03/31/2015 14,900 4,800 47.53 22
    TOWER RESEARCH CAPITAL LLC (TRC) 03/31/2015 11,823 11,119 1,579.40 17
    WELLS FARGO & COMPANY/MN 03/31/2015 10,501 0 0.00 16

    Sentiment: Strong Sell

  • So, funds/institutions are buying, MNKD insiders are buying, Mann group is holding, Sanofi is paying hundreds million of milestones and will pay up to $1B.
    But stubborn shorts are short-selling. Who will be winner in this game?

    May 21, 2015 KRESA KENT
    Director
    36,268 Direct Acquisition (Non Open Market) at $0 per share. N/A
    May 21, 2015 NORDHOFF HENRY L
    Director
    26,481 Direct Acquisition (Non Open Market) at $0 per share. N/A
    May 21, 2015 CONSIGLIO RONALD J
    Director
    31,374 Direct Acquisition (Non Open Market) at $0 per share. N/A
    May 21, 2015 MACCALLUM DAVID
    Director
    26,481 Direct Acquisition (Non Open Market) at $0 per share. N/A
    May 21, 2015 MARTENS JUERGEN
    Officer
    20,000 Direct Automatic Purchase at $4.57 per share. 91,400
    May 21, 2015 FRIEDMAN MICHAEL A
    Director
    11,800 Direct Acquisition (Non Open Market) at $0 per share. N/A
    May 21, 2015 SHANNON JAMES SAMUEL
    Director
    11,800 Direct Acquisition (Non Open Market) at $0 per share. N/A

    Sentiment: Strong Buy

  • Shorts have only 20 days to cover this huge 131M short positions. Afrezza TV commercial will attract an attention of millions diabetics in USA and worldwide. EMA filing should follow advertising in USA.
    STRONG BUY will be next recommendation for MNKD.

    Sentiment: Strong Buy

  • biotech_invest biotech_invest Jun 10, 2015 11:29 AM Flag

    LOL! I'm so scared by your profanity :-) I hope PRAN-scam pps will be $20 before phase III HD trial results release and I'll have possibility to short this #$%$ at high (like I did last time). But before I'll use run up to make good money. So, if I mistake I'll lose big money and you will be well-established prophet for new biotech gem Prana. I promise I'll go away in tears and praying for your wisdom:-)
    About comparison of Mann and Tanzi: first one already gave people pacemakers, very convenient insulin inhalator and recently a Second Sigh (Bionic Eyes); Tanzi promised to cure AD/HD/PD with simple chemicals and currently these drugs failed for AD, almost fail for HD and will fail for PD. Actually it's Tanzi is biggest narcissist and braggart: in each interview he repeat again and again that he had discovered AD-related genes but he was just first author in published paper but not correspondent author (so he just did simple lab work that his lab supervisor asked him to do). Now Tanzi states that he has founded 2 biotechs that will discover cures for AD, HD, PD and etc. But he will never find these cures. Just a miserable buffoon in comparison with Dr. Mann.

    Sentiment: Strong Sell

  • So it's possible to short 131M shares if float is just 122M? By naked shorting? If it's true shorts were really desperate and now they are in tight trap. When Sanofi start TV commercial for Afrezza all funds and retails will only BUY MNKD.

    Sentiment: Strong Buy

  • In this case they are in big troubles now i.e. 100% underwater. Funds will easy crash shorts even by small size (1-2M shares) Market orders.

    Sentiment: Strong Buy

  • biotech_invest biotech_invest Jun 9, 2015 4:06 PM Flag

    come on, I don't care about any respects from PRAN pumpers like you. Who said to short PRAN when PRAN pps was $10 and everybody were waiting for phenomenal AD trial results?
    May be it was you? But according YMB you are Member since: Oct 20, 2014. So you should not remember this nice time :-)
    LOL! "Real knowledge of biotech in your comments" :-)
    May you have real knowledge and will predict right now a success of future (if any) phase III HD trial?
    Basing on my knowledge of biotech my prediction will be: complete FAILURE. But before we will have nice run up and wise investors will make good money on both Prana run up and final crash.
    Don't worry I will be here and never will change my nickname or add any numbers to it :-)

    Sentiment: Strong Sell

  • BOSTON (TheStreet) -- Fiftteen biotech predictions for 2015:

    2. By the end of the year, Sanofi (SNY) will jettison MannKind (MNKD) and its failed inhaled insulin Afrezza.

    Question: will TheStreet by the end of the year jettison Adam Feuerstein because of all 15 his stupid predictions were wrong?
    What if Sanofi acquire MNKD by the end of the year and all shorts will get enormous losses like $2-3 billion on 120-130M short interest?

    Sentiment: Strong Buy

  • biotech_invest biotech_invest Jun 9, 2015 2:23 PM Flag

    Specially for rkf from dictionaryDOTreferenceDOTcom
    stupid
    [stoo-pid, styoo‐]
    Spell Syllables
    Examples Word Origin
    adjective, stupider, stupidest.
    1.
    lacking ordinary quickness and keenness of mind; dull.

    May be humanity will have AD curing drug but unfortunately people will never have drug for foolishness and stupidity.
    Once again some advice for old farter RKF: get some rest and change your ddult diapers - you are just FOS (full of sh...t).

  • biotech_invest biotech_invest Jun 9, 2015 12:28 PM Flag

    The question is why stupidest pumper of PRAN rkf302 continues adding numbers 1 to his stupid nickname? His posts are mostly ignored because they contain zero information i.e. it's only "malediction diarrhea"
    Get some rest, old farter, or you will become insane in nearest future (if not already).

  • Do you think that your stupid posts can increase 18 cents pps of PBT (or $1.39 pps of PRAN)?
    Useless attempts, paid pumper :-) Who hired you? Tanzi?
    Or you have huge losses with both PBT and PRAN and want to compensate them by pumping this fake biotech?
    About your question why I post here while I know that PRAN is fake biotech: I make money with both fake biotechs and biotech gems. But I never hide my opinions about these companies. PRAN in fake biotech list and putting it in this list before HD/AD trials failures helped me to have a huge gains on both run up and crash. So, I'm here to make money again and will be here before PRAN (or PBT) is still alive.

    Sentiment: Strong Sell

SNY
49.28-0.80(-1.60%)Aug 28 4:02 PMEDT